Evaluation of <scp>D</scp>utch guideline for just‐in‐time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte–colony‐stimulating factor

Abstract

Application of the HOVON guideline on the just-in-time administration of plerixafor is effective for mobilization of hematopoietic stem cells in the majority of patients. Stem cell yield in patients with non-Hodgkin lymphoma was lower compared to patients with multiple myeloma. Also patients with very low circulating CD34+ cells before addition of plerixafor might benefit from this approach.